BELEODAQ
Total Payments
$1.3M
Transactions
5,501
Doctors
2,823
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $348,658 | 1,430 | 991 |
| 2023 | $637,213 | 1,233 | 895 |
| 2022 | $279,109 | 1,654 | 1,071 |
| 2021 | $79,198 | 1,184 | 858 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $586,993 | 312 | 43.7% |
| Unspecified | $449,540 | 45 | 33.4% |
| Food and Beverage | $79,852 | 3,717 | 5.9% |
| Grant | $70,000 | 1 | 5.2% |
| Space rental or facility fees (teaching hospital only) | $61,300 | 17 | 4.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $55,578 | 66 | 4.1% |
| Travel and Lodging | $21,137 | 68 | 1.6% |
| Education | $16,527 | 1,273 | 1.2% |
| Honoraria | $3,250 | 2 | 0.2% |
Payments by Type
General
$894,638
5,456 transactions
Research
$449,540
45 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| IIS-BEL-009 | Acrotech Biopharma Inc. | $135,016 | 0 |
| SPI-BEL-301 | Acrotech Biopharma Inc. | $77,692 | 0 |
| Global outcomes of single agents vs combination chemotherapy for patients with R/R peripheral T-cell and NK/T-cell lymphoma | Acrotech Biopharma LLC | $54,359 | 0 |
| IIS-BEL-023 | Acrotech Biopharma Inc. | $23,257 | 0 |
| IIS-BEL-021 | Acrotech Biopharma Inc. | $21,744 | 0 |
| IIS-BEL-003 | Acrotech Biopharma Inc. | $15,452 | 0 |
| Therapeutic outcomes of novel agents vs conventional chemotherapy in clinical trials in patients with newly diagnosed and R/R mature T and NK/T-cell lymphomas: a meta- analysis study | Acrotech Biopharma LLC | $13,000 | 0 |
| IIS-BEL-011 | Acrotech Biopharma Inc. | $9,975 | 0 |
| IIS-BEL-012 | Acrotech Biopharma Inc. | $9,958 | 0 |
| SPI-BEL-502 | Acrotech Biopharma Inc. | $9,375 | 0 |
| SPI-BEL-107 | Acrotech Biopharma Inc. | $9,200 | 0 |
| IIS-BEL-P-001 | Acrotech Biopharma Inc. | $5,239 | 0 |
| IIS-BEL-020 | Acrotech Biopharma Inc. | $4,154 | 0 |
| IIS-BEL-P-002 | Acrotech Biopharma Inc. | $119.70 | 0 |
Top Doctors Receiving Payments for BELEODAQ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $581,328 | 69 |
| , MD | Medical Oncology | New York, NY | $130,171 | 11 |
| , MD | Medical Oncology | New Haven, CT | $35,487 | 20 |
| , M.D | Hematology & Oncology | Tampa, FL | $34,655 | 24 |
| , M.D | Hematology & Oncology | New York, NY | $27,557 | 30 |
| , D.O | Internal Medicine | Omaha, NE | $25,315 | 26 |
| , MD, PHD | Hematology | Columbus, OH | $18,874 | 21 |
| , M.D | Hematology & Oncology | Philadelphia, PA | $18,748 | 17 |
| , M.D | Hematology & Oncology | Seattle, WA | $18,270 | 21 |
| , M.D | Specialist | Los Angeles, CA | $14,400 | 1 |
| , MD | Internal Medicine | Miami, FL | $13,708 | 12 |
| , M.D | Hematology | Rochester, MN | $13,698 | 13 |
| , MD | Internal Medicine | Aurora, CO | $12,099 | 18 |
| , M.D | Hematology & Oncology | Rochester, MN | $11,900 | 1 |
| , MD | Hematology & Oncology | Los Angeles, CA | $11,773 | 13 |
| , MD | Hematology & Oncology | Cleveland, OH | $10,802 | 14 |
| , MD | Hematology & Oncology | Cleveland, OH | $10,800 | 1 |
| , M.D | Hematology & Oncology | Boston, MA | $10,725 | 1 |
| , MD | Hematology & Oncology | Cleveland, OH | $10,500 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $9,217 | 14 |
| , M.D | Medical Oncology | Houston, TX | $9,000 | 1 |
| , M.D., PH.D | Medical Oncology | New York, NY | $8,634 | 13 |
| , M.D | Internal Medicine | Boston, MA | $8,571 | 5 |
| , MD | Hematology | Greenwich, CT | $8,417 | 5 |
| , MD | Internal Medicine | Boston, MA | $8,203 | 5 |
Ad
Manufacturing Companies
- Acrotech Biopharma Inc. $985,871
- Acrotech Biopharma LLC $358,307
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 2,823
- Transactions 5,501
About BELEODAQ
BELEODAQ is a drug associated with $1.3M in payments to 2,823 healthcare providers, recorded across 5,501 transactions in the CMS Open Payments database. The primary manufacturer is Acrotech Biopharma LLC.
Payment data is available from 2021 to 2024. In 2024, $348,658 was paid across 1,430 transactions to 991 doctors.
The most common payment nature for BELEODAQ is "Consulting Fee" ($586,993, 43.7% of total).
BELEODAQ is associated with 14 research studies, including "IIS-BEL-009" ($135,016).